Not dapagliflozin
The amazing thing about this research is that dapagliflozin 10 mg/day seemed to benefit patient who didn’t even have diabetes. Unfortunately, the abstract doesn’t mention how many non-diabetic patients were in the study.
Conclusion from the abstract:
Among patients with heart failure and a reduced [left ventricular] ejection fraction [under 40%], the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.
Source: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM
Paleo Diabetic 